A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

被引：12

作者：

Facon, Thierry ^{[1
]}

Hulin, Cyrille ^{[2
]}

Dimopoulos, Meletios A. ^{[3
]}

Belch, Andrew ^{[4
]}

Meuleman, Nathalie ^{[5
]}

Mohty, Mohamad ^{[6
]}

Chen, Wen-Ming ^{[7
]}

Kim, Kihyun ^{[8
]}

Zamagni, Elena ^{[9
]}

Rodriguez-Otero, Paula ^{[10
]}

Renwick, William ^{[11
]}

Rose, Christian ^{[12
]}

Tempescul, Adrian ^{[13
]}

Palumbo, Antonio ^{[14
]}

Guo, Shien ^{[15
]}

Sturniolo, Michael ^{[16
]}

Ervin-Haynes, Annette ^{[16
]}

Fermand, Jean-Paul ^{[17
]}

机构：

[1] CHRU Lille, Hop Claude Huriez, Malad Sang, F-59037 Lille, France

[2] CHU BORDEAUX, Bordeaux, France

[3] Univ Athens, Sch Med, Athens 11528, Greece

[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[5] Univ Libre Bruxelles, Jules Bordet Insitute, Dept Hematol, Brussels, Belgium

[6] St Antoine Hosp, Dept Haematol, Paris, France

[7] Beijing Chaoyang Hosp, Beijing, Peoples R China

[8] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[9] Azienda Osped Univ, Bologna, Italy

[10] Univ Navarra Clin, Pamplona, Spain

[11] Western Hlth, St Albans, Australia

[12] Hop St Vincent, Dept Hematol, Lille, France

[13] CHU Brest, Dept Hematol, F-29285 Brest, France

[14] Univ Turin, Turin, Italy

[15] Evidera, Boston, MA USA

[16] Celgene Corp, Summit, NJ USA

[17] Hop St Louis, AP HP, Serv Immunohematol, Paris, France

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.4239.4239

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ
Manier, Salomon
Dimopoulos, Meletios-Athanasios
Leleu, Xavier
Moreau, Philippe
Cavo, Michele
Goldschmidt, Hartmut
Orlowski, Robert Z.
Tron, Muriel
Tekle, Christina
Bregeault, Marie-France
Shafer, Andrea
Beksac, Meral
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S290 - S291
[22] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
BLOOD, 2022, 140 : 10133 - 10136
[23] FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT).
Facon, Thierry
Hulin, Cyrille
Dimopoulos, Meletios A.
Belch, Andrew
Reece, Donna Ellen
Catalano, John V.
Pinto, Antonio
Ludwig, Heinz
Bahlis, Nizar J.
Cavo, Michele
Moreau, Philippe
Qiu, Lugui
LeBlanc, Richard
Schots, Rik
Rajkumar, S. Vincent
Marek, Jennifer
Chen, Guang
Ervin-Haynes, Annette L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[24] Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial
Hulin, Cyrille
Facon, Thierry
Shustik, Chaim
Belch, Andrew
Petrucci, Maria Teresa
Duehrsen, Ulrich
Lu, Jin
Song, Kevin
Rodon, Philippe
Pegourie, Brigitte
Garderet, Laurent
Hunter, Hannah
Azais, Isabelle
Eek, Richard
Macro, Margaret
Dakhil, Shaker
Houck, Vanessa
Chen, Guang
Ervin-Haynes, Annette
Offner, Fritz
BLOOD, 2014, 124 (21)
[25] UPDATED OVERALL SURVIVAL ANALYSIS OF THE FIRST STUDY: CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE VS MELPHALAN, PREDNISONE, AND THALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Facon, T.
Dimopoulos, M. A.
Hulin, C.
Benboubker, L.
Belch, A.
Ludwig, H.
Pinto, A.
Attal, M.
Cavo, M.
Moreau, P.
Schots, R.
Meuleman, N.
Weisel, K.
Tiab, M.
Lee, J. J.
Butler, A.
Marek, J.
Chen, G.
Ervin-Haynes, A.
Fermand, J. P.
HAEMATOLOGICA, 2015, 100 : 3 - 3
[26] Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
Suzuki, Kenshi
Shinagawa, Atsushi
Uchida, Toshiki
Taniwaki, Masafumi
Hirata, Hirokazu
Ishizawa, Kenichi
Matsue, Kosei
Ogawa, Yoshiaki
Shimizu, Takayuki
Otsuka, Maki
Matsumoto, Morio
Iida, Shinsuke
Terui, Yasuhito
Matsumura, Itaru
Ikeda, Takashi
Takezako, Naoki
Ogaki, Yumi
Midorikawa, Shuichi
Houck, Vanessa
Ervin-Haynes, Annette
Chou, Takaaki
CANCER SCIENCE, 2016, 107 (05) : 653 - 658
[27] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Rajkumar, S. Vincent
Jacobus, Susanna
Callander, Natalie S.
Fonseca, Rafael
Vesole, David H.
Williams, Michael E.
Abonour, Rafat
Siegel, David S.
Katz, Michael
Greipp, Philip R.
LANCET ONCOLOGY, 2010, 11 (01): : 29 - 37
[28] Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients
Chou, Takaaki
Shinagawa, Atsushi
Uchida, Toshiki
Taniwaki, Masafumi
Hirata, Hirokazu
Ishizawa, Kenichi
Matsue, Kosei
Ogawa, Yoshiaki
Shimizu, Takayuki
Otsuka, Maki
Matsumoto, Morio
Iida, Shinsuke
Terui, Yasuhito
Matsumura, Itaru
Ikeda, Takashi
Takezako, Naoki
Ogaki, Yumi
Midorikawa, Shuichi
Houck, Vanessa
Ervin-Haynes, Annette
Suzuki, Kenshi
BLOOD, 2014, 124 (21)
[29] Effect of Treatment with Lenalidomide Plus Low-Dose Dexamethasone Until Progression on Health-Related Quality of Life Over Time in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Vogl, Dan T.
Delforge, Michel
Song, Kevin
Guo, Shien
Gibson, Craig J.
Ervin-Haynes, Annette
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E87 - E87
[30] EFFECT OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE TREATMENT UNTIL PROGRESSION ON HEALTH-RELATED QUALITY OF LIFE OVER TIME IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Vogl, D. T.
Delforge, M.
Song, K.
Guo, S.
Gibson, C. J.
Ervin-Haynes, A.
Facon, T.
HAEMATOLOGICA, 2016, 101 : 145 - 145

← 1 2 3 4 5 →